amyloid beta-protein

Amyloid beta-protein(1-40) Arctic variant (Ab40ARC (E22G)), featuring a glycine at position 22 (Gly22), is a peptide utilized in Alzheimer's disease research [1].

β-Amyloid (22-35) is a 14-aa peptide, shows aggregates and induces neurotoxicity in the hippocampal cells. Beta amyloid (22-35) is a synthetic truncated fragment of beta-amyloid peptide.

β-Amyloid (1-28), a fragment of the β-Amyloid protein, is involved in metal binding.

Amyloid β-peptide fragment; minimum section required to bind to brain proteins. Binds with high affinity to α7-nicotinic ACh receptors, and impairs memory retention following central administration in mice in vivo.

β-Amyloid (1-16) is an amyloidogenic protein fragment derived from the β-amyloid sequence, known for its ability to bind metal ions, indicating its role in metal-binding processes. β-Amyloid, a peptide, is responsible for forming amyloid plaques in the brains of people with Alzheimer's disease (AD).

β-Amyloid (1-15) (Amyloid β-Protein (1-15)) is a fragment of β-amyloid protein used in the study of Alzheimer's disease.

β-Amyloid (29-40) is a fragment of Amyloid-β peptide. Alzheimer's beta amyloid peptide (29-40/42) C-terminal fragments exhibit physical and chemical properties similar to fusion peptides of viral proteins, inducing liposome fusion in vitro.

β-amyloid (12-28) TFA, a peptide fragment of β-amyloid protein (β1-42), is the major component of senile plaque cores. β-amyloid (12-28) has aggregation properties and the potential for Alzheimer's disease research.

β-Amyloid (29-40) acetate is a fragment of the β-amyloid peptide and can be used in related research on Alzheimer's disease.

Amyloid β-Protein (10-20) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease.Amyloid β protein fragment containing the α-secretase processing site (Lys16-Leu17 bond). It also contains the HHQK domain (residues 13-16) re

Amyloid β-Protein 10-20 acetate (Amyloid β-Protein 10-20 acetate (152286-31-2 free base)) is a fragment of Amyloid-β peptide, maybe used in the research of neurological disease.Amyloid β protein fragment containing the α-secretase processing site (Lys16-Leu17 bond). It also contains the HHQK domain (residues 13-16) responsible for binding to microglial cells.

HEPPS exhibits inhibitory activity against the amyloid-beta precursor protein, reducing Aβ aggregation burden and improving neuronal autophagy flux, thereby alleviating neuronal apoptosis and traumatic brain injury (TBI) in mice. It can be used for research into Alzheimer's disease and neurological disorders.

Umibecestat is an inhibitor of beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1), with IC50s of 11 nM and 10 nM for human BACE-1 and mouse BACE-1, respectively. Umibecestat can be used for the research of alzheimer's disease.

Begacestat (GSI-953) is a potent and selective gamma-secretase inhibitor (γ-secretase) that inhibits Amyloid-beta production with nanomolar potency, selectively inhibits cleavage of APP in cellular level Notch cleavage assays, reverses situational memory deficits, and can be used to study Alzheimer's disease.

JBPOS0101 modulates amyloid-beta protein, tau protein, and glial cells in Alzheimer's disease models.

Aβ aggregation-IN-1 (Compound 1b) is an inhibitor of amyloid-beta precursor protein. It suppresses the aggregation and disaggregation of amyloid-beta fibrils with IC50 values of 3.92 and 7.19 M, respectively. Additionally, Aβ aggregation-IN-1 reduces malondialdehyde formation in neuronal cells, increases intracellular levels of reduced glutathione (GSH), and inhibits caspase 3.

Multitarget AD inhibitor-2 (Compound VN-19) is a versatile inhibitor targeting multiple sites, acting on acetylcholinesterase (AChE, IC50 = 0.14 μM), butyrylcholinesterase (BChE, IC50 = 11.6 μM), and monoamine oxidase B (MAO B, IC50 = 0.45 μM). It inhibits amyloid-beta protein Aβ1-42 self-induced aggregation with an inhibition rate of 47.3% at 20 μM and reduces ROS levels in SH-SY5Y cells with an inhibition rate of 80% at 25 μM. Multitarget AD inhibitor-2 can also improve cognitive decline in a scopolamine-induced Alzheimer's zebrafish model.

CHF-5022 is a nonsteroidal anti-inflammatory drug that selectively inhibits the production of beta-amyloid protein (1-42) (ABETA42).

BACE-IN-1 is amyloid precursor protein beta-secretase inhibitor

Human beta-amyloid protein 42 (1-7) is a bioactive chemical.

AChE/BChE/BACE-1-IN-1 (Compound 4k) is an orally active inhibitor that targets acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and β-site amyloid precursor protein cleaving enzyme 1 (BACE-1), with IC50 values of 0.058 μM, 0.082 μM, and 0.115 μM against hAChE, hBChE, and hBACE-1, respectively. It exhibits significant binding affinity with PAS-AChE, excellent blood-brain barrier permeability, potential disassembly of amyloid-beta (Aβ) aggregates, neuroprotective properties against Aβ-induced stress, and remarkable antioxidant capabilities [1].

FITC-β-Ala-Amyloid β-Protein (1-42) (ammonium) is a fluorescein isothiocyanate (FITC)-tagged monomeric peptide of amyloid beta 1-42, which plays a critical role in the pathogenesis of Alzheimer’s disease, making FITC-β-Ala-Amyloid β-Protein (1-42) (ammonium) a valuable tool for mechanistic studies, drug screening, and biomolecular investigations related to neurodegenerative processes.

'(Asp37)-Amyloid β-Protein (1-42) [1]' refers to the G37D mutant variant of the wild-type Amyloid-beta (1-42) peptide.

Bapineuzumab (AAB-001) is a humanised monoclonal antibody targeting amyloid-beta (Aβ), capable of binding to the N-terminal region of both soluble and oligomeric forms of amyloid β, and is used for research into Alzheimer's disease (AD).